Neurolixis Inc. has been selected by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to be showcased in its Partnering Program. The program presents promising MJFF portfolio projects directly to industry groups that may wish to invest in further development of the awardee’s research.The MJFF has previously awarded four research grants to Neurolixis to carry out detailed preclinical studies of its exceptionally-selective and efficacious serotonin 5-HT1A receptor agonist, NLX-112, a promising Phase 2 candidate for treatment of L-DOPA-induced dyskinesia (LID). LID can cause considerable discomfort to Parkinson's disease (PD) patients and is a source of distress for patients and their families. No approved drug treatment for LID is currently available.

Neurolixis is currently exploring mechanisms to fund the clinical testing of NLX-112 in PD patients suffering from LID. As Neurolixis is a MJFF grant awardee, details of the company, its program and team are made available by the MJFF for review by industry groups.

Read the Neurolixis press release: 

Visit the Michael J. Fox Foundation Partnering Program page.

Download the Neurolixis Partnering Document.